Humana Appoints Roy A. Beveridge, M.D., as Chief Medical Officer

Business Wirevia The Motley Fool
Updated

Humana Appoints Roy A. Beveridge, M.D., as Chief Medical Officer

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Humana Inc. (NYS: HUM) , one of the nation's leading health and well-being companies, announced today that Roy A. Beveridge, M.D. has been appointed Senior Vice President and Chief Medical Officer, effective June 17.

Dr. Beveridge will serve on the company's Executive Team and report to President and Chief Executive Officer Bruce Broussard. He'll be responsible for developing Humana's clinical strategy as well as policies for clinical employees (associates) across Humana's clinical organizations.


"Given his strong leadership, clinical expertise and deep understanding of the health care consumer, Dr. Beveridge is well positioned for success," Broussard said. "He will play an important leadership role in helping us create a collaborative and engaging environment for our providers. As Humana looks to expand our care delivery capabilities, a key element of the company's integrated care delivery model, Dr. Beveridge will be instrumental in enabling us to achieve this important objective."

Dr. Beveridge is currently Chief Medical Officer for McKesson Specialty Health, a subsidiary of McKesson Corporation based in The Woodlands, Tex. Prior to McKesson's acquisition of US Oncology in 2010 he served as the Executive Vice President and Medical Director at US Oncology. Dr. Beveridge was also the Co-Director of the Bone Marrow Transplant Program at INOVA Fairfax Hospital in Falls Church, Virginia.

"Humana's dedication as a longstanding advocate for encouraging providers to move from pay-for-service to pay-for-value and better health outcomes is vital to addressing the health care challenges we face today," Dr. Beveridge said. "I'm looking forward to ensuring our members receive quality, affordable health care through a consistent, best-in-class clinical experience."

Board certified in medical oncology and internal medicine Dr. Beveridge has authored numerous articles on a wide range of medical topics such as hematology, stem cell transplantation and quality/value-based medical practice. He has more than 25 years of experience in the medical community.

Dr. Beveridge earned a Bachelor of Arts degree in Biology/Cell Biology from Johns Hopkins University and a medical degree from Cornell University Medical College. He completed his residency in internal medicine at University of Chicago Hospitals and his fellowship at Johns Hopkins University.

About Humana

Humana Inc., headquartered in Louisville, Ky., is a leading health-care company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. By leveraging the strengths of its core businesses, Humana believes it can better explore opportunities for existing and emerging adjacencies in health care that can further enhance wellness opportunities for the millions of people across the nation with whom the company has relationships.

More information regarding Humana is available to investors via the Investor Relations page of the company's web site at www.humana.com, including copies of:

  • Annual reports to stockholders

  • Securities and Exchange Commission filings

  • Most recent investor conference presentations

  • Quarterly earnings news releases

  • Replays of most recent earnings release conference calls

  • Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)

  • Corporate Governance information



Humana Inc.
Tom Noland, 502-580-3674
Corporate Communications
tnoland@humana.com
or
Regina Nethery, 502-580-3644
Investor Relations
rnethery@humana.com

KEYWORDS: United States North America Kentucky

INDUSTRY KEYWORDS:

The article Humana Appoints Roy A. Beveridge, M.D., as Chief Medical Officer originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement